Date Title PDF Version
11/17/22 Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
11/09/22 Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
11/08/22 Aadi Bioscience Announces Planned Leadership Transition
11/03/22 Aadi Bioscience to Present at Upcoming Investor Conferences
11/02/22 Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
10/27/22 Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
10/12/22 Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
10/12/22 Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
09/22/22 Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
09/01/22 Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
08/10/22 Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
07/28/22 Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
06/23/22 Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
06/01/22 Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
05/31/22 Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
05/26/22 Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
05/18/22 Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
05/12/22 UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
05/12/22 Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
05/09/22 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
05/04/22 Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
04/28/22 Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
04/18/22 Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
04/08/22 Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
03/31/22 Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes
03/17/22 Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03/01/22 Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
02/23/22 Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
01/04/22 Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference